Literature DB >> 27657899

Lymphoma of the nasal cavity and paranasal sinuses: A case series.

Toby O Steele1, Maria C Buniel, Jess C Mace, Edward El Rassi, Timothy L Smith.   

Abstract

BACKGROUND: Lymphomas of the sinonasal tract are a rare and heterogeneous subset of solid sinonasal neoplasms.
OBJECTIVE: To characterize, in this case series, presenting symptoms, treatment modalities, and outcomes for patients with sinonasal lymphoma within a single institution.
METHODS: Retrospective patient data were collected from an academic, oncologic center and entered into a repository designed to capture outcomes for sinonasal malignancies. Patient demographics, presenting symptoms, imaging findings, treatment modalities, and health status were retrospectively extrapolated and evaluated by using Kaplan-Meier estimations for survival probability.
RESULTS: Patients with sinonasal lymphoma with a mean follow-up of 50 months were identified (n = 18). Histologic diagnosis included the following: diffuse large B-cell lymphoma (n = 9), natural killer/T-cell lymphoma (n = 5), follicular lymphoma (n = 1), T-cell lymphoma (n = 1), and lymphoma-not otherwise specified (n = 2). The most frequent presenting symptoms were nasal obstruction (78%), facial pain (72%), facial swelling (50%), and nasal discharge (44%). Treatment before lymphoma diagnosis included antibiotics (83%), oral steroids (22%), decongestants (22%), and topical steroids (11%). Treatment regimens after diagnosis included both chemotherapy (94%) and chemoradiotherapy (56%). Survival rates by lymphoma subtype were 56% for B-cell lymphoma and 40% for natural killer/T-cell lymphoma. Overall, 2- and 5-year survival rates were 67% and 50%, respectively. The combination of chemotherapy and radiation resulted in significantly higher survival rates (p ≤ 0.001) than chemotherapy alone.
CONCLUSION: Sinonasal lymphomas are characterized by meager survival rates, which differ by histopathologic subtype. The diagnosis of sinonasal lymphoma is challenging because symptoms frequently parallel those of chronic rhinosinusitis. Increased awareness of these rare malignancies may improve detection and more timely treatment. Clinical trial registration NCT01332136.

Entities:  

Mesh:

Year:  2016        PMID: 27657899     DOI: 10.2500/ajra.2016.30.4347

Source DB:  PubMed          Journal:  Am J Rhinol Allergy        ISSN: 1945-8932            Impact factor:   2.467


  6 in total

1.  Reality bites: The establishment of accountable care organizations in otolaryngology.

Authors:  Troy D Woodard
Journal:  Am J Rhinol Allergy       Date:  2016-09       Impact factor: 2.467

2.  Histopathology of Sinonasal and Nasopharyngeal Neoplastic Lesions in a Tertiary Care Center of Western Nepal: A Descriptive Cross-sectional Study.

Authors:  Sudeep Regmi; Arnab Ghosh; Dilasma Gharti Magar; Sushma Thapa; Krishna Prasad Koirala; Om Prakash Talwar
Journal:  JNMA J Nepal Med Assoc       Date:  2021-07-30       Impact factor: 0.556

3.  Primary Sinonasal Lymphoma: A Rare Cause of Cranial Neuropathies.

Authors:  Raman J Sohal; Sylva Bem; Diana M Gilligan
Journal:  Cureus       Date:  2020-05-15

4.  Primary sinonasal lymphoma in immunocompetent patients: A 10 years retrospective clinicopathological study.

Authors:  Nadia Shirazi; Sampan Singh Bist; Neeti Puri; Meena Harsh; Sohaib Ahmad
Journal:  J Oral Maxillofac Pathol       Date:  2018 May-Aug

5.  Survival analysis of 8785 malignant lymphoma cases in the oral and nasal cavities in the USA: a cohort study.

Authors:  Feifei Jiang; Ai-Hui Yan
Journal:  BMJ Open       Date:  2021-12-15       Impact factor: 2.692

6.  Nasopharyngeal Lymphoma: A 22-Year Review of 35 Cases.

Authors:  Chien-Yu Hsueh; Ching-Fen Yang; Jyh-Pyng Gau; Edward C Kuan; Ching-Yin Ho; Tzeon-Jye Chiou; Liang-Tsai Hsiao; Ting-An Lin; Ming-Ying Lan
Journal:  J Clin Med       Date:  2019-10-03       Impact factor: 4.241

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.